Alpelisib (Piqray) is a phosphatidylinositol-3-kinase (PI3K) inhibitor. It is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer confirmed to have PIK3CA gene mutations via FDA-approved testing. It is used in combination with fulvestrant for patients whose disease has progressed following endocrine therapy.

How to Purchase Alpelisib (Piqray)

Overseas Purchase

Patients may choose to consult and purchase the medication at hospital pharmacies or legitimate drugstores in countries or regions where alpelisib has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and can offer professional consultation and guidance.

Important Precautions for Purchasing Alpelisib (Piqray)

Medical Evaluation

A comprehensive medical evaluation must be conducted before medication use, including assessments of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), liver function, infection risk, and cardiac function.

Patient Selection

PIK3CA mutation must be confirmed by testing.

The patient has previously received endocrine therapy and experienced disease progression.

No severe renal impairment (caution is required for CLcr < 30 mL/min).

No history of severe hypersensitivity or active pneumonia.

Drug Interactions

Avoid concurrent use with strong CYP3A4 inducers (e.g., rifampicin).

Avoid simultaneous use with breast cancer resistance protein (BCRP) inhibitors.

When used in combination with fulvestrant, strictly follow the dosage guidelines for fulvestrant (500 mg intramuscular injection on Days 1, 15, and 29, followed by once monthly thereafter).

Authenticity Verification of Alpelisib (Piqray)

Packaging and Label Inspection

Genuine alpelisib is manufactured by Novartis. The packaging should clearly display the drug name, batch number, expiration date, and FDA approval number.

Each box contains 2 blister packs (56 tablets in total) and is designed with child-resistant packaging.

Physical Property Verification

50 mg tablets: Light pink, unmarked, round with curved edges.

150 mg tablets: Light red, unmarked, oval with curved edges.

200 mg tablets: Light red, unmarked, oval with curved edges.

Information Tracing and Verification

Medications purchased through legitimate channels are accompanied by traceable information. Patients can verify the authenticity of the medication through official channels.